Koshinski Asset Management
ONCT

Koshinski Asset Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Koshinski Asset Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$2.78K – 2072
2022
Q1 		$2.78K Hold
100
– – ﹤0.01% 1910
2021
Q4 		$4.54K Buy
+100
New +$6.73K ﹤0.01% 1828

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Koshinski Asset Management's ONCT Position: Q2 2022 in Review

Koshinski Asset Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 100 shares — an estimated $2.78K sold.

Koshinski Asset Management first reported a position in ONCT in Q4 2021 and held it in 2 quarters. The position peaked at $4.54K in Q4 2021. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

  • Koshinski Asset Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 100 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $2.78K.
  • Koshinski Asset Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Koshinski Asset Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $4.54K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.